Galectin-3 (Gal-3) is a member of the family of β-galactoside-binding mammalian lectins known as galectins. 1 To date, 14 galectins have been described and various members of the galectin family have been shown to modulate cell growth, cell adhesion and cell apoptosis. 2 Galectin-3 has been reported to be expressed in the nucleus, in the cytoplasm and on the cell surface, and can be secreted without a signal peptide into the extracellular compartment by an unusual secretory mechanism. 3 Several in vitro and in vivo studies have demonstrated a possible role for this protein in tumour invasion, metastatic cascade and inflammation. 2, 4, 5 High serum Gal-3 concentrations have been reported in patients with advanced colorectal carcinoma, breast cancer and melanoma. 6 We recently demonstrated Gal-3 expression in melanoma. 7 We suggest two modalities, which are not mutually exclusive, to explain the possible roles of a high serum level of Gal-3 in patients with advanced melanoma (Fig. 1 ).
The first modality is that released Gal-3 could directly facilitate the metastatic process through the interaction of metastatic cancer cells with vascular endothelium and the adhesion of melanoma cells to elastin-rich tissues such as skin and lung tissue. 1, 2, 5, 8 Gal-3 is known to participate in the linking of cancer cells to capillary endothelium and to enhance adhesion of cancer cells to extracellular matrix proteins such as laminin, elastin and collagen IV. Many other adhesion molecules such as integrins, cadherins, carbohydrates and carbohydrate-binding proteins have already been implicated in tumour cell-endothelium interactions and the metastatic process; this highlights the complexity of the multistep adhesion process in which Gal-3 may play a role.
The second modality is that Gal-3 release could directly enhance inflammation, which can be related to tumour burden in cancer patients (Fig. 1) . Gal-3 is known to be proinflammatory: this lectin, which can be produced by inflammatory cells, has been shown to depress the apoptosis of inflammatory cells. 9 This anti-apoptotic effect of Gal-3, which has been widely discussed in the literature, gives cells a selective survival advantage. 10 Such an advantage may be particularly important in the vascular compartment, in which inflammatory and circulating tumoural cells can be found in patients with metastatic disease.
New markers of disease progression and surrogate prognostic indicators in melanoma patients are needed, 11, 12 and Gal-3 may have a possible role as a soluble marker for the metastatic process in such patients. The biological significance of Gal-3 and the mechanism by which it is released from melanoma and/or inflammatory cells remain to be elucidated.
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